Braveheart Bio
PublicBraveheart Bio is now publicly traded
The data on this page reflects Braveheart Bio's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Aug 5, 2026
Last Round
Series A
Nov 5, 2025
Total Funding Raised
$567.5M
Company Overview
Braveheart Bio is a biotechnology company developing novel therapeutics for hypertrophic cardiomyopathy and related cardiovascular conditions.
AI Layer
Non-AI
Keywords
Braveheart Bio Comparables
Compare Braveheart Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Zhejiang Jixing Auto Parts Co., Ltd. | 81% | |
| Bristol Myers Squibb | 80% | |
| Cytokinetics, Incorporated | 79% |
For institutional investors. Book with your work email.
Braveheart Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | Aug 5, 2026 | ||||
| Series A | Nov 5, 2025 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Braveheart Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Andreessen Horowitz | Series A |
| Enavate Sciences | Series A |
| Forbion | Series A |
| Fidelity Management & Research Company | IPO |
| OrbiMed | Series A |
| Frazier Life Sciences | Series A |
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventNov 6, 2026
Braveheart Bio, Inc. is to host Investor Event and Webcast on Nov 6th '26, including discussion of the planned fixed-dose oHCM study TRUEHEART-HCM.
- attends_eventOct 30, 2026
Braveheart presents two studies, including late-breaking 52-week extension data for BHB-1893 in obstructive HCM, at American Heart Association Scientific Sessions 2026 in Illinois on Nov 6th-9th '26.
- is_developingSep 18, 2026
In California on Sep 19th '26, Braveheart is developing BHB-1893, an oral cardiac myosin inhibitor for obstructive and non-obstructive hypertrophic cardiomyopathy, and is testing it against metoprolol in a global Phase 3 trial.
- attends_eventSep 16, 2026
Braveheart is to participate in the Stifel Virtual Cardiometabolic Forum on Sep 30th '26, with management taking part in a fireside chat at 12:30 p.m. EDT.
- attends_eventSep 1, 2026
Braveheart is set to participate in the Cantor Global Healthcare Conference in New York on Sep 9th–11th '26, with management participating in a fireside chat on Sep 10th '26.
For institutional investors. Book with your work email.
Braveheart Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.